Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide.
Unresectable or metastatic HCC has a poor prognosis, and systemic cytotoxic …

Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed
worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced …

Accumulated understanding of the molecular pathways regulating cancer progression has
led to the development of novel targeted therapies. Hepatocellular carcinoma (HCC) …

With an annual incidence of over 660,000 deaths, hepatocellular carcinoma (HCC) is the
third leading cause of cancer death globally. This disease is often diagnosed at an …

Hepatocellular carcinoma (HCC) is one of the most frequent tumors worldwide. The majority
of HCC cases occur in patients with chronic liver disease. Despite regular surveillance to …

Hepatocellular carcinoma (HCC) is a highly lethal disease that is resistant to conventional
cytotoxic drugs. Historically, effective systemic treatment options have not been available for …

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most
common cause of cancer-related mortality worldwide. Despite decades of efforts by many …

In recent years, molecular-targeted agents have been used clinically to treat various
malignant tumors. In May 2009, sorafenib (Nexavar®) was approved in Japan for …

Conventional systemic chemotherapy has been developed with so-called anti-cancer
agents, essentially screened for cytotoxicity to cultured cancer cells. However, in patients …

Opinion statement Hepatocellular carcinoma (HCC) is one of the most lethal cancers
globally, particularly in certain regions of the world. Although the major risk factors for HCC …